2018/02/22
Shanghai, February 22, 2018 - STA Pharmaceutical Co., Ltd. (STA), a WuXi AppTec company and the leading open-access capability and technology platform for small molecule pharmaceutical development and manufacturing, and Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announce they have entered into an oligonucleotide synthesis collaboration agreement for research and mid-scale non-GMP/cGMP manufacturing.
Read more2017/11/17
Philadelphia, November 17 2017 – WuXi AppTec (WuXi), a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform company, announced that its Advanced Therapy Unit based in Philadelphia has been selected as a manufacturing partner for advanced therapies through the California Institute for Regenerative Medicine (CIRM) funded IQVIA (formerly QuintilesIMS) Stem Cell Center.
Read more2017/10/18
SHANGHAI, China & AUSTIN, Texas, Oct. 18, 2017 - WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform, today announced that it has acquired ResearchPoint Global (RPG), a US-based contract research organization (CRO) with expertise spanning across all major therapeutic areas.
Read more2017/10/09
SHANGHAI, Oct. 9, 2017 -- WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform, today announced that it has been awarded the 2017 Frost & Sullivan Global Integrated Drug R&D Services Competitive Strategy Innovation & Leadership Award.
Read more2017/07/31
Shanghai, July 31, 2017: STA Pharmaceutical Co., Ltd. (STA) – a WuXi AppTec company and the leading open-access capability and technology platform for small molecule pharmaceutical development and manufacturing – announces that it has merged with WuXi AppTec’s Pharmaceutical Development Services (PDS) division.
Read more